Erasmus Medical Center
Rotterdam, Nederland, 3015CN, Netherlands
NCT Number: NCT02265588
The presented study aims to reduce symptoms of depression and anxiety in adolescents with inflammatory bowel disease and increased symptoms of anxiety and depression by using the disease specific CBT program (PASCET-PI)in order to improve quality of life and to improve the clinical course of disease.
Looking for future studies?
Notify Me10 year–20 year
All sexes
Interventional
Not applicable
Rotterdam, Nederland, 3015CN, Netherlands
For patients in the CBT group, 13 sessions (6 outpatient sessions, 7 by phone) and three parental sessions will take place in a hospital close to their home. Our study population consists of adolescents and young adults with IBD, as this is a specific group with high reported symptoms of depression and anxiety, therefore they will most likely benefit from the intervention. The risks associated with participation can be considered negligible and the burden minimal. For the time investment of completing the questionnaires participants will receive an incentive of 25 euro after the final assessment, which will be communicated at the start.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
A disease specific cognitive behavioral therapy program called PASCET-PI: The PASCET-PI model focuses on behavioral activation, cognitive restructuring and problem solving skills to change maladaptive behaviors, cognitions and coping strategies specific for IBD.
Time frame: 12 weeks and 52 weeks
Measured by the Child Depression Inventory (CDI (10-17 years), Beck Depression Inventory (BDI; 18-25 years) and severity rating (interview): the Children's Depression Rating Scale (CDRS;10-12 years) and Adolescent Depression Rating Scale(ADRS;13-20 years), HAM-D: Hamilton Depression Rating Scale (21-25 year)
Time frame: 12 weeks and 52 weeks
Measured by SCARED-NL: Screen for Anxiety Related Emotional Disorders (10-20 years), Hospital Anxiety and Depression Scale (HADS; 21-25 year) and severity rating by Pediatrix Anxiety Rating Scale (PARS) (10-20 years) ,Hamilton Anxiety Rating (HAM-A)(21-25 year)
Time frame: 12 weeks and 52 weeks
Assessed by the Child Health Related Quality of Life (TACQOL) (10-15 years) Adult Health Related Quality of Life (TAAQOL, 16-25 years)
Time frame: 12 weeks
Assessed by Social Skills Rating System (SSRS) (10-20years) Novotni SSC: Social Skills Checklist (21-25 year)
Time frame: 12 weeks
Assessed by Youth Self Report (YSR) / Adult Self Report (ASR)
Time frame: 12 weeks and 52 weeks
Assessed by the IMPACT-III-NL (10-20years) IBDQ: Inflammatory Bowel Disease Questionnaire (21-25 year)
Time frame: 52 weeks
Assessed by the Pediatric Ulcerative Colitis Activity Index (PUCAI) (10-20 years) Pediatric Crohn's Disease Activity Index (PCDAI) (10-20 years) CDAI: Crohn's Disease Activity Index (21-25 years) Partial Mayo Score (21-25 years) Physician Global Assessment (PGA)
Time frame: 52 weeks
10-20 Years: Relapse for CD is defined as PCDAI>30 or an increase of>15 points and intensification of medical treatment.
Relapse for UC is defined as PUCAI > 34 or an increase of ≥20 points for UC and intensification of medical treatment.
21-25 years: Partial Mayo score of 3 or higher with intensification of medical treatment Or CDAI≥ 150 and an increase in baseline CDAI score of ≥ 70 points and intensification of medical treatment
Time frame: 52 weeks
Remission is defined as PCDAI < 10 for CD and PUCAI < 10 for UC. CDAI < 150 and Mayo score ≤2 with no individual subscore > 1
Time frame: 52 weeks
Type and dosage of medication
Time frame: 52 weeks
Description of type and extent of surgical intervention
Time frame: 52 weeks
Assessed by the Morisky Medical Adherence Scale (MASS-8)
Time frame: 52 weeks
Assessed by standardized items derived from the questionnaires and Report of the treating physician.
Time frame: baseline and 12, 24 and 52 weeks
Inflammatory markers will be measured at all time points (baseline and after 3,6,12 months) Inflammatory markers like BSE, CRP, faecal calprotectin
Time frame: 12 weeks
Assesses by the Brief Illness Perceptions Questionnaire (B-IPQ)
Time frame: 12 weeks
Assesses by the Cognitive Emotion Regulation Questionnaire (CERQ)
Time frame: 12 weeks
Assesses by the Sleep Self-Report (SSR) (10-20 years) PSQI: Pittsburgh Sleep Quality Index (21-25 year)
Time frame: 12 weeks
Assesses by the Rotterdam's quality of life interview
Time frame: 12 weeks
Assesses by the Depression, Anxiety and Stress Scale (DASS-21)
Time frame: 12 weeks
Assesses by the Life events questionnaire from CERQ
Time frame: 12 weeks
Assesses by the Family Assessment Device (FAD)
Time frame: 52 weeks
Assessed by the Paris Classification
Time frame: 52 weeks
The treatment strategy, type and dosage of medication will be extracted from the medical file and report of the treating physician.
Time frame: 12 weeks
Assessing immune status is done by analyzing gene expression profiles in peripheral blood leukocytes. This will be performed
Time frame: 12 weeks
A blood sample will be taken in all patients included within the Erasmus MC for determination of responsiveness of peripheral blood lymphocytes before and directly after the intervention
Time frame: 12 months
Assessed by the ROME III diagnostic criteria for IBS in pediatric IBD patients
Erasmus Medical Center
Other
Reducing Symptoms of Depression and Anxiety in Adolescents With Inflammatory Bowel Disease in Order to Improve Quality of Life and the Clinical Course of Disease.
Acronym: HAPPY-IBD
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04806620
ARFID, Ankylosing Spondylitis (AS)
Delafield, Wisconsin, United States
View Trial DetailsNCT05384080
Colitis, Colitis, Ulcerative
Wroclaw, Dolnoslskie, Poland
View Trial DetailsNCT05596422
Colitis, Colitis, Ulcerative
Taichung, Taiwan
View Trial DetailsNCT07590518
Anxiety, Anxiety Disorders
Los Angeles, California, United States
View Trial Details